GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Preliminary, Unaudited Financial Results Preliminary, unaudited revenue for the fourth qua. ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly†, "the company†), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2025 of at least 17% year over year. Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2025 Revenue Growth of at least 17% Year over Year. Share About Butter ...

Core Insights - FORGE is hosting the Make It Here: CT Product Development Grant Awards on January 22, 2026, to announce the latest grant recipients aimed at supporting Connecticut manufacturers and hardtech companies [1] - The FORGE Connecticut Product Development Grant program, backed by the Manufacturing Innovation Fund, assists local manufacturers in overcoming product development challenges and fostering in-state supplier relationships [2][3] - The event will feature a panel discussion on the future of regional manufacturing and guided tours of Kubtec Medical Imaging's facility [3][4] Company Overview - FORGE is a nonprofit organization that aids hardtech innovators and emerging manufacturing companies in product development and scaling production [5] - The organization has supported over 1,000 innovators and contributed to the creation of over 10,000 jobs in innovation and manufacturing sectors [6] Event Details - The Make It Here event will include a panel discussion titled "Fueling Connecticut's Emerging Manufacturers: Capital, Collaboration and the Future of Regional Manufacturing" [3] - M&T Bank is presenting the event, highlighting its commitment to supporting local manufacturers and innovators [3]

Company Overview - Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, including X-ray tubes, digital detectors, and image processing solutions [2] - The company has over 70 years of successful innovation in the field of X-ray imaging [2] - Varex's products are utilized in medical imaging as well as industrial and security imaging applications [2] - The company is headquartered in Salt Lake City, Utah, and employs approximately 2,400 people across North America, Europe, and Asia [2] Upcoming Event - Management of Varex Imaging Corporation is scheduled to present at the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference [1] - The presentation is set for Wednesday, January 14, 2026, at 3:50 PM ET [1] - The webcast of the presentation can be accessed through Varex's website [1]

Core Viewpoint - FONAR Corporation has entered into a definitive merger agreement with FONAR, LLC and FONAR Acquisition Sub, Inc., where the Buyer will acquire all outstanding shares of FONAR for specified cash amounts per share, subject to certain conditions [1][2]. Transaction Details - The cash offer includes $19.00 per share for common and Class B stock, $6.34 for Class C stock, and $10.50 for Class A non-voting preferred stock [1]. - The transaction price represents a 31.5% premium over the last closing price before the announcement, a 21.9% premium over the price on July 8, 2025, and a 39.7% premium over the average closing price for the 90 days ending June 30, 2025 [3]. - The transaction is expected to close in the third fiscal quarter of 2026, pending approval from the Company's stockholders and other customary conditions [4]. Financing Structure - The acquisition will be financed through a combination of new debt, new equity, and rollover of Company securities, with a secured debt financing facility of $35 million from OceanFirst Bank [6]. - Additional debt of approximately $10 million and equity of about $45 million will be provided by members of the Acquisition Group and third-party lenders [6]. Advisory and Legal Support - Marshall & Stevens Transaction Advisory Services LLC is the financial advisor to the Special Committee, while Meister Seelig & Fein PLLC provides legal counsel to the Special Committee [7]. - DLA Piper LLP (US) serves as legal counsel to FONAR, and Moritt Hock & Hamroff LLP is legal counsel to the Buyer [7]. Company Background - FONAR Corporation, established in 1978, is recognized as the inventor of MR Scanning and is the oldest MRI company in the industry [15]. - The company is known for its FONAR UPRIGHT® Multi-Position™ MRI, which allows for imaging in various weight-bearing positions, enhancing diagnostic capabilities [16]. - FONAR's primary income source is its diagnostic imaging management subsidiary, Health Management Company of America [18].

Group 1 - Philips N.V. is characterized as a "set it and forget it" company, indicating a stable investment with long-term potential in the imaging and image-guided therapies sectors [1] - The company is recognized as one of the world leaders in its fields, which enhances its attractiveness to investors [1] Group 2 - The article emphasizes the importance of conducting due diligence and research prior to any investment, highlighting that the author is not providing financial advice [2] - It is noted that investing in European and Scandinavian stocks may involve specific withholding tax risks, which investors should consider [2]

Austin, Texas, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Elastography Imaging Market Size & Growth Analysis: According to SNS Insider, the Elastography Imaging Market size was valued at USD 3.27 billion in 2024 and is projected to reach USD 5.88 billion by 2032, growing at a CAGR of 7.66% over the forecast period of 2025–2032. The increasing demand for non-invasive diagnostic procedures, particularly for liver fibrosis, oncology, and musculoskeletal disorders, is significantly contributing to market growth. Elastog ...

Company Overview - Guerbet is a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging [5] - The company has been a pioneer in contrast agents for 98 years and employs 2,905 people worldwide [6] - Guerbet dedicated 9% of its revenue to Research & Development across four centers in France and the United States [6] - In 2024, Guerbet achieved €841 million in revenue [6] Appointment of François Convenant - François Convenant has been appointed as Senior Vice President of Interventional Radiology and will join the Guerbet Group's Executive Committee [1] - He joined Guerbet in September 2018 and has extensive international experience in the healthcare and medical device sector [2] - His previous roles involved management positions at leading companies, focusing on innovation and growth in surgical solutions and interventional devices [2] Interventional Radiology Insights - Interventional radiology is a rapidly expanding medical specialty that combines advanced imaging with minimally invasive therapeutic procedures [3] - This field is experiencing rapid growth due to an aging population and increasing demand for less invasive treatments [3] - Technological innovations, including AI, robotics, and precision imaging, are enhancing the safety and effectiveness of procedures [3] - The economic and clinical impact includes reduced costs related to complications and improved quality of life for patients [4] Guerbet's Mission and Offerings - Guerbet aims to meet the needs of healthcare institutions and practitioners by providing integrated and innovative solutions [4] - The company combines drugs, medical devices, services, and technologies, supported by dedicated training programs to enhance clinical practices [4]

Core Insights - GE HealthCare (GEHC) has formed a strategic partnership with Indonesia's Ministry of Health under the SIHREN program to enhance access to advanced diagnostic and care technologies across Indonesia [1][2][4] Partnership Details - The SIHREN initiative will see GEHC support the deployment of medical technologies, training, and digital health solutions to improve the national referral hospital network [2][4] - GEHC is set to supply over 300 advanced CT scanners to Indonesia's public healthcare system, benefiting over 280 million people and enhancing diagnostic capabilities nationwide [8][9] - The agreement is structured as a multi-year contract awarded through a competitive international tender process, ensuring transparency and adherence to World Bank regulations [8][9] Market Position and Stock Performance - Following the announcement, GEHC shares remained flat in after-market trading, but the stock has increased by 34.7% over the past six months, contrasting with a 1.2% decline in the industry [3][7] - GEHC currently has a market capitalization of $38.47 billion [6] Industry Outlook - The global medical imaging market is projected to grow from $41.6 billion in 2024 to $55.4 billion by 2030, with a CAGR of 4.95% from 2025 to 2030, driven by rising chronic disease prevalence and demand for early diagnosis [11]

Core Viewpoint - Royal Philips has announced the acquisition of SpectraWAVE, Inc., which specializes in Enhanced Vascular Imaging (EVI) and AI applications in medical imaging, aimed at improving treatment for coronary artery disease, a condition affecting over 300 million people globally [2][4][6]. Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation [15][16]. - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people [16]. Acquisition Details - The acquisition of SpectraWAVE will enhance Philips' portfolio in the coronary intervention segment, integrating AI-powered innovations in intravascular imaging and physiological assessment [4][7][9]. - Financial terms of the acquisition have not been disclosed [13]. Technology Integration - SpectraWAVE's HyperVue Imaging System combines DeepOCT and NIRS technologies to provide detailed imaging of coronary arteries during procedures, facilitating rapid setup and automated AI analysis [8][10]. - The X1-FFR technology from SpectraWAVE offers AI-enabled physiological assessments from a single angiogram, enhancing the workflow for percutaneous coronary interventions [11]. Market Impact - The integration of SpectraWAVE's technologies with Philips' Azurion platform is expected to significantly increase the adoption of advanced imaging and physiological assessment in treating coronary artery disease [9][12]. - Philips aims to expand clinician choice and improve patient outcomes through the convergence of intravascular imaging, coronary physiology, and AI [6][7].